Overview

3,3'-Diindolylmethane in Patients With Systemic Lupus Erythematosus

Status:
Terminated
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This is a single center study of patients with inactive or mild SLE being performed to determine the safety, tolerability, and pharmacodynamics of DIM.
Phase:
Phase 1
Details
Lead Sponsor:
Northwell Health
Treatments:
3,3'-diindolylmethane